2024-06-27 09:51:48 ET
Summary
- Assertio Holdings, Inc. shares present a significant upside potential due to ongoing turnaround efforts and proven success in monetizing underappreciated pharma assets.
- The merger with Spectrum Pharmaceuticals saved Assertio from potential collapse after a generic drug approval, providing a new opportunity with Rolvedon.
- A DCF valuation model suggests a fair equity value of $4.00 per share, indicating a potential 300% upside from the current share price, but high risks are involved.
...
Read the full article on Seeking Alpha
For further details see:
Assertio: An Extremely Asymmetric Bet Skewed To The Upside